A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Occurrence of grade ≥2 Cytokine Release Syndrome (CRS)

Part 1

Time frame: Up to 28 days

Timing of grade ≥2 CRS

Part 1

Time frame: Up to 28 days

Overall Survival (OS)

Part 2

Time frame: Up to 7 years

Achievement of Partial Response (PR) or better per IMWG response criteria as determined by BIRC

Part 2

Time frame: Up to 5 years

Achievement of Very Good Partial Response (VGPR) or better per IMWG response criteria as determined by BIRC

Part 2

Time frame: Up to 5 years

Achievement of CR or better per IMWG response criteria as determined by BIRC

Part 2

Time frame: Up to 5 years

Duration Of Response (DOR) as per IMWG response criteria

Part 2

Time frame: Up to 5 years

Time To Progression (TTP) as per IMWG response criteria

Part 2

Time frame: Up to 5 years

Time To Next Treatment (TTNT)

Part 2

Time frame: Up to 5 years

Second PFS

Part 2

Time frame: Up to 5 years

MRD-negative CR criteria at any time

Part 2

Time frame: Up to 5 years

Time to PR IMWG response category

Part 2

Time frame: Up to 5 years

Time to VGPR IMWG response category

Part 2

Time frame: Up to 5 years

Time to CR IMWG response category

Part 2

Time frame: Up to 5 years

Time to stringent Complete Response (sCR) IMWG response category

Part 2

Time frame: Up to 5 years

Sustained MRD-negative CR

Part 2

Time frame: Up to 5 years

Duration of MRD-negative CR

Part 2

Time frame: Up to 5 years

Occurrence of TEAEs

Part 2

Time frame: Up to 5 years

Severity of TEAEs

Part 2

Time frame: Up to 5 years

Occurrence of AESIs

Part 2

Time frame: Up to 5 years

Severity of AESIs

Part 2

Time frame: Up to 5 years

Occurrence of SAEs

Part 2

Time frame: Up to 5 years

Severity of SAEs

Part 2

Time frame: Up to 5 years

Concentrations of linvoseltamab in serum over time

Part 2

Time frame: Up to 5 years

Incidence of Antidrug Antibodies (ADAs) to linvoseltamab

Part 2

Time frame: Up to 5 years

Magnitude of ADAs to linvoseltamab

Part 2

Time frame: Up to 5 years

Concentrations total soluble B-cell Maturation Antigen (sBCMA) in serum over time

Part 2

Time frame: Up to 5 years

Change from baseline in Global Health Status (GHS)/Quality of Life (QoL), per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Part 2 The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported QoL using 1 GHS/QoL scale, 5 functioning scales (physical, role, emotional, cognitive and social) and 9 symptom scales / items (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) among patients with cancer. Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."

Time frame: Up to 5 years

Change from baseline in Physical Functioning (PF), per EORTC QLQ-C30

Part 2

Time frame: Up to 5 years

Change from baseline in Role Functioning (RF), per EORTC QLQ-C30

Part 2

Time frame: Up to 5 years

Change from baseline in pain, per EORTC QLQ-C30

Part 2

Time frame: Up to 5 years

Change from baseline in fatigue, per EORTC QLQ-C30

Part 2

Time frame: Up to 5 years

Change in patient reported Disease Symptoms (DS) per EORTC Quality of Life Questionnaire-Multiple Myeloma (MM) module 20 [QLQ-MY20])

Part 2 EORTC QLQ-MY20 is an accompanying 20-item validated questionnaire that measure quality of life among patients living with MM across 4 scales (disease symptoms, side effect of treatment, body image and future perspective). A high score represents a high level of symptoms or problems.

Time frame: Up to 5 years

Change in patient reported Treatment Side Effects (TSE) per EORTC QLQ-MY20

Part 2

Time frame: Up to 5 years

Change in patient-reported health state per EuroQoL-5 Dimension-5 Level Scale [EQ-5D-5L]) Visual Analogue Scale (VAS)

Part 2 The EQ-5D-5L is a generic questionnaire that measures HRQoL across 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) across 5 levels (no problems, slight problems, some problems, severe problems and extreme problems) and a VAS of pain (where 0: no pain and 10: worst pain), higher scores indicate higher pain.

Time frame: Up to 5 years

Change in patient-reported overall impact of treatment per Functional Assessment of Chronic Illness Therapy (FACIT) item GP5

Part 2 FACIT Item GP5 is a recommended item by the Federal Drug Administration (FDA) in its recent draft guidance for cancer trials to assess patient-reported overall impact of treatment toxicity. It uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much)

Time frame: Up to 5 years